Reduced asymmetric dimethylarginine (ADMA) levels mediate in the protection from metabolic syndrome by smoking

Atherosclerosis

Volumn 196, Issue 1, 2008, Pages 479-480

  Onat, Altan ^a   Hergenç, Gülay ^b  

^a ISTANBUL UNIVERSITY   (Turkey)

^b YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine; Cigarette smoking; Insulin resistance; Metabolic syndrome; Obesity

Indexed keywords

ARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE;

BLOOD PRESSURE; BODY MASS; CIGARETTE SMOKING; ENDOTHELIAL DYSFUNCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LETTER; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL;

ARGININE; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; SMOKING;

EID: 38049069183     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.10.040     Document Type: Letter

References (5)

1. Onat A, Ozhan H, Esen AM, Albayrak S, Karabulut A, Can G, Hergenc G. Prospective epidemiologic evidence of a "protective" effect of smoking on metabolic syndrome and diabetes among Turkish women-without associated overall health benefit. Atherosclerosis 2006 Aug 18 [Epub ahead of print].
2. Eid H.M., Arnesen H., Hjerkinn E.M., Lyberg T., and Seljeflot I. Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 53 (2004) 1574-1579
3. Onat A., Avci{dotless} G.S., Barlan M.M., et al. Measures of abdominal obesity assessed for visceral adiposity and relation to coronary risk. Int J Obes 28 (2004) 1018-1025
4. Schnabel R., Blankenberg S., Lubos E., et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97 (2005) e53-e59
5. Chan N.N., and Chan J.C. Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome?. Diabetologia 45 (2002) 1609-1616